During Monday's "Lightning Round" segment of Mad Money, one caller asked Jim Cramer about the prospects for CRISPR Therapeutics (CRSP) : "A company like this isn't bought on earnings, it's bought on speculation. As long as you're OK with that, I'll bless it," responded Cramer.
More from Investing
You've probably been told timing the market is futile, but here's a way to make it possible -- if you're willing to do the work.
Along with the media proclamation of a bear market, we have some improvement in the charts of many smaller stocks, but ...
Let's take a technical follow-up look at MDB -- and give a word of caution on this software name.
For investors looking to take advantage of lofty oil and gas prices, we like these investment vehicles.